Pharming Group

Pharming Group Liabilities

The The Liabilities of Pharming Group (PHARM.AS) as of Nov 16, 2026 is 222.89 M USD. In the previous year, The Liabilities was 178.85 M USD — a change of 24.63% (higher).

Liabilities

222.89 MUSD

YoY

24.63%

Last updated:

In 2025, Pharming Group's total liabilities amounted to 222.89 M USD, a 24.63% difference from the 178.85 M USD total liabilities in the previous year.

The Pharming Group Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
174.81 M USD
Jan 1, 2019
138.38 M USD
Jan 1, 2020
235.39 M USD
Jan 1, 2021
204.19 M USD
Jan 1, 2022
221.16 M USD
Jan 1, 2023
228.28 M USD
Jan 1, 2024
178.85 M USD
Jan 1, 2025
222.89 M USD
The Pharming Group Liabilities history
YEARLiabilitiesYoY
222.89 MUSD+24.63%
178.85 MUSD-21.66%
228.28 MUSD+3.22%
221.16 MUSD+8.31%
204.19 MUSD-13.26%
235.39 MUSD+70.11%
138.38 MUSD-20.84%
174.81 MUSD-1.14%
176.82 MUSD+69.29%
104.45 MUSD+182.34%
37.00 MUSD+17.58%
31.46 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Pharming Group's Liabilities

Pharming Group's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pharming Group's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pharming Group's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pharming Group's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pharming Group’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pharming Group stock

The Liabilities of Pharming Group is 222.89 M USD in 2025.

The Liabilities of Pharming Group changed from 178.85 M USD to 222.89 M USD, representing a 24.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Pharming Group since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Pharming Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Pharming Group

All Key Metrics — Pharming Group